TECENTRIQ + Carbo/Etop: The First FDA-Approved Treatment for 1L ES-SCLC in 20 Years 2,3


  • More than 40 Phase III trials evaluating other regimens have been attempted since 1970, none of which led to additional FDA approvals 4

The first and only FDA-approved cancer immunotherapy combination to improve overall survival in 1L ES-SCLC 2

  • Median OS was 12.3 months with TECENTRIQ + carbo/etop vs 10.3 months with placebo + carbo/etop (HR=0.70; 95% CI, 0.54, 0.91; P=0.0069)
  • PD-L1 testing is not required to prescribe TECENTRIQ for ES-SCLC

NCCN CATEGORY 1 PREFERRED: Atezolizumab (TECENTRIQ) + carbo/etop is a category 1 preferred immunotherapy/chemotherapy option for first-line treatment of patients with ES-SCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 1*

*NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Guidelines® for detailed recommendations.
Preferred interventions are based on efficacy, safety, and evidence.

1L=first line; carbo/etop=carboplatin/etoposide; CI=confidence interval; HR=hazard ratio; ES-SCLC=extensive-stage small cell lung cancer; NCCN=National Comprehensive Cancer Network; OS=overall survival; PD-L1=programmed death-ligand 1.